We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies. Close

News in brief

Pharmaceutical Law Insight

News in brief

Merck settles Zetia patent suit UNITED STATES Merck & Co has settled its patent litigation against generic drug firm Glenmark Pharmaceuticals over Merck’s cholesterol lowering drug Zetia (ezetimibe). The case was set to go to trial on 12 May, after Glenmark sought US Food and Drug Administration approval to market a generic version of ezetimibe, which is still under patent protection until April 2017. Under terms of the settlement, Glenmark will be able to sell ezetimibe from December 2016.

The rest of this document is only available to i-law.com online subscribers.

If you are already a subscriber, please enter your details below to log in.

Enter your email address to log in as a user on your corporate account.
Remember me on this computer

Not yet an i-law subscriber?

Devices

Request a trial Find out more